AIM: To investigate the clinical effect of conbercept intravitreal injection combined with macular grid laser photocoagulation on the treatment of diabetic macular edema(DME).

METHODS: Forty patients(40 eyes)with diabetic macular edema were randomly divided into experimental group(20 cases)and control group(20 cases). Both groups received macular grid laser photocoagulation, and the experimental group combined with intravitreal injection of conbercept on the same day. At 45d later the experimental group received intravitreal injection of conbercept again. The central macular thickness(CMT)and best corrected visual acuity(BCVA)of the two groups were compared before and at 45 and 90d after treatments.

RESULTS: At 45d after the treatment, the data of CMT between two groups was significant difference(experimental group: 293.90±12.94μm, control group: 320.20±29.17μm; P<0.05). At 90d after the treatment, the data of CMT between two groups was significant difference(experimental group: 265.80±16.26μm, control group: 290.15±12.23μm; P<0.05). At 45d after the treatment, the data of BCVA between two groups was significant difference(experimental group: 0.40±0.08, control group: 0.34± 0.04, P<0.05). At 90d after the treatment, the data of BCVA between two groups was significant difference(experimental group: 0.46±0.09; control group: 0.37±0.06; P<0.05).

CONCLUSION: Conbercept intravitreal injection combined with macular grid laser photocoagulation on the treatment of DME is much better on improving visual acuity and reducing macular edema than the grid laser photocoagulation treatment alone. For extension of the time of Conbercept intravitreal injection can be more scientific or not, still needs further research.